Search company, investor...

Middlebrook Pharmaceuticals

middlebrookpharma.com

Founded Year

1999

Stage

Dead | Dead

Total Raised

$105.66M

About Middlebrook Pharmaceuticals

MiddleBrook Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products that fulfill unmet medical needs. It was formerly known as Advancis Pharmaceuticals. MiddleBrook currently markets KEFLEX, the immediate-release brand of cephalexin, and MOXATAG - the first and only FDA-approved once-daily amoxicillin. nnThe companyhas developed a proprietary delivery technology called PULSYS, which enables the pulsatile delivery, or delivery in rapid bursts, of certain drugs. MOXATAG is our first product utilizing our proprietary PULSYS technology. While MiddleBrook is currently focused on the anti-infective arena, we see opportunities for PULSYS products in the anti-fungal, antiviral, and oncology markets as well.

Headquarters Location

20425 Seneca Meadows Parkway Suite 100

Germantown, Maryland, 20876,

United States

301-944-6600

Missing: Middlebrook Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Middlebrook Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Middlebrook Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Middlebrook Pharmaceuticals is included in 1 Expert Collection, including Cancer.

C

Cancer

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

Middlebrook Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was Middlebrook Pharmaceuticals founded?

    Middlebrook Pharmaceuticals was founded in 1999.

  • Where is Middlebrook Pharmaceuticals's headquarters?

    Middlebrook Pharmaceuticals's headquarters is located at 20425 Seneca Meadows Parkway, Germantown.

  • What is Middlebrook Pharmaceuticals's latest funding round?

    Middlebrook Pharmaceuticals's latest funding round is Dead.

  • How much did Middlebrook Pharmaceuticals raise?

    Middlebrook Pharmaceuticals raised a total of $105.66M.

  • Who are the investors of Middlebrook Pharmaceuticals?

    Investors of Middlebrook Pharmaceuticals include Rho Ventures, Tang Capital Management, Federated Equity Funds - Federated Kaufmann Fund, Millennium Management, Clarion Capital Partners and 20 more.

  • Who are Middlebrook Pharmaceuticals's competitors?

    Competitors of Middlebrook Pharmaceuticals include Intarcia Therapeutics, Acton Pharmaceuticals, NovoLogix, Supernus Pharmaceuticals, Wilmington Pharmaceuticals and 11 more.

Compare Middlebrook Pharmaceuticals to Competitors

A
Advent Pharmaceuticals

Advent Pharmaceuticals is a specialty pharmaceutical company focused on developing inhaled drug products using a dry powder inhalation delivery system. The products are mostly used for the treatment of asthma and other respiratory diseases.

I
IVREA Pharmaceuticals

IVREA Pharmaceuticals is a specialty pharmaceutical company focused on clinical development and commercialization of novel prescription pharmaceuticals for the treatment of dermatologic conditions. IVREA's pharmaceuticals leverage topical delivery technologies.

F
Frio Pharmaceuticals

Frio Pharmaceuticals is dedicated to oral-systemic health and was spun out of Biomedical Development Corporation (BDC), its research affiliate, in 1999 to manufacture and sell a dental waterline cleaner. This platform technology has evolved into a pipeline of pharmaceuticals to treat oral diseases and interrupt the disease process. Its goal is to commercialize a broad-spectrum antimicrobial platform technology with products being: (1) a pharmaceutical to treat thrush (oral candidiasis) in cancer patients with thrush and (2) a pharmaceutical to treat gingivitis (oral inflammation).

K
Kytogenics Pharmaceuticals Limited

Kytogenics is a medical device company. It had developed the Nocc Hydrophilic Wound Dressing.Kytogenics Pharmaceuticals, Inc. is a biomedical company engaged in the development of products based on its medical device and drug delivery patented platform technology.

W
Wilmington Pharmaceuticals

Wilmington Pharmaceuticals believes in fixing missed opportunities in established pharmaceutical products. With this product strategy, the company enjoys streamlined regulatory approval paths, relatively low R&D costs, and lower risks than traditional pharmaceutical product development programs. The company is currently completing the final clinical trial required for their initial product -- a fast dissolving version of a nausea and gastric distress product. This new product addresses proven market needs with improved delivery systems that are familiar to physicians and welcomed by patients. Wilmington Pharmaceuticals will begin work later this year on an improved version of a major pain drug.

Aerogen Logo
Aerogen

Aerogen specializes in the design, manufacture and commercialization of aerosol drug delivery systems. Aerogen's patented vibrating mesh technology turns liquid medication into a fine particle mist, gently and effectively delivering drugs to the lungs of patients, enhancing outcomes and giving healthcare professionals a higher level of confidence and control.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.